Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M522Revenue (TTM) $M18.9Net Margin (%)-380.4Altman Z-Score10.0
Enterprise Value $M396EPS (TTM) $-1.0Operating Margin %-385.1Piotroski F-Score1
P/E(ttm)--Beneish M-Score-2.6Pre-tax Margin (%)-380.5Higher ROA y-yN
Price/Book4.110-y EBITDA Growth Rate %0.9Quick Ratio10.2Cash flow > EarningsY
Price/Sales27.25-y EBITDA Growth Rate %9.4Current Ratio10.2Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-42.4Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-48.2Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M71.9ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with SGMO

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

SGMO is held by these investors:



SGMO: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Herberts Curt A. IIISenior VP & CBO 2017-05-12Sell2,639$8.02-9.6view
LANPHIER EDWARD O IIPresident & CEO 2015-07-15Sell25,000$10.43-30.49view
Wolff Henry WardExec VP & CFO 2015-07-13Sell12,000$10-27.5view
LANPHIER EDWARD O IIPresident & CEO 2015-06-15Sell25,000$11.08-34.57view
Wolff Henry WardExec VP & CFO 2015-06-10Sell12,000$12.21-40.62view
ANDO DALE GVP, Therapeutic Dev. & CMO 2015-06-05Sell15,000$12.29-41.01view
RINGO WILLIAM RDirector 2015-06-03Sell2,200$12.44-41.72view
Gregory Philip DSVP of Research & CSO 2015-06-01Sell15,000$12.39-41.49view
LANPHIER EDWARD O IIPresident & CEO 2015-05-15Sell25,000$11.51-37.01view
Wolff Henry WardExec VP & CFO 2015-05-11Sell12,000$13.25-45.28view

Quarterly/Annual Reports about SGMO:

News about SGMO:

Articles On GuruFocus.com
Sangamo Receives Fast Track Designation From The FDA For SB-525 Investigational Hemophilia A Gene Th May 16 2017 
Sangamo Therapeutics Recognizes International MPS Awareness Day And Celebrates The MPS I And MPS II May 15 2017 
Sangamo Therapeutics Presents Recent Developments from Research and Clinical Programs at Annual Meet May 15 2017 
Sangamo Therapeutics And Pfizer Announce Collaboration For Hemophilia A Gene Therapy May 10 2017 
Sangamo Therapeutics Reports First Quarter 2017 Financial Results May 10 2017 
Sangamo Therapeutics Announces Special Regulatory Designations from the FDA for Three Clinical Progr May 04 2017 
Sangamo Therapeutics Announces First Quarter 2017 Conference Call And Webcast May 03 2017 
Sangamo Announces The Retirement Of Its Founder And Genome Editing Pioneer Edward Lanphier From The Apr 25 2017 
Sangamo Therapeutics Announces Presentations at 2017 Annual meeting of the American Society of Gene Apr 24 2017 
Sangamo Therapeutics Announces Participation In The ARM 5th Annual Cell & Gene Therapy Investor Day Apr 24 2017 

More From Other Websites
ETFs with exposure to Sangamo Therapeutics, Inc. : May 25, 2017 May 25 2017
Sangamo Therapeutics, Inc. :SGMO-US: Earnings Analysis: Q1, 2017 By the Numbers : May 24, 2017 May 24 2017
Will Sangamo Therapeutics (SGMO) Continue to Surge Higher? May 18 2017
Sangamo's (SGMO) Hemophilia A Drug Gets Fast-Track Status May 17 2017
Edited Transcript of SGMO earnings conference call or presentation 10-May-17 9:00pm GMT May 17 2017
Sangamo Receives Fast Track Designation From The FDA For SB-525 Investigational Hemophilia A Gene... May 16 2017
Sangamo Therapeutics Recognizes International MPS Awareness Day And Celebrates The MPS I And MPS II... May 15 2017
Is the Options Market Predicting a Spike in Sangamo Therapeutics (SGMO) Stock? May 15 2017
Sangamo Therapeutics Presents Recent Developments from Research and Clinical Programs at Annual... May 15 2017
Why Sangamo Therapeutics Inc. Jumped Higher Today May 12 2017
Today's Research Reports on Stocks to Watch: Conatus Pharmaceuticals and Sangamo Therapeutics May 12 2017
Sangamo Therapeutics, Inc. – Value Analysis (NASDAQ:SGMO) : May 11, 2017 May 11 2017
Here's Why Sangamo Therapeutics Rocketed Up to 56.3% Higher Today May 11 2017
Why Sangamo Therapeutics Is Surging May 11 2017
Sangamo shares jump on Pfizer collaboration, quarterly results May 10 2017
Sangamo reports 1Q loss May 10 2017
Sangamo Therapeutics And Pfizer Announce Collaboration For Hemophilia A Gene Therapy May 10 2017
Sangamo Therapeutics Reports First Quarter 2017 Financial Results May 10 2017
Sangamo Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : SGMO-US : May 9,... May 09 2017
Blog Coverage: Sangamo Receives Special Regulatory Designation from FDA for Three of Its Program May 05 2017

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)